Race and association with disease manifestations and mortality in scleroderma : A 20-year experience at the johns hopkins scleroderma center and review of the literature

Medicine (United States)

Volumn 92, Issue 4, 2013, Pages 191-205

  Gelber, Allan C ^a   Manno, Rebecca L ^a   Shah, Ami A ^a   Woods, Adrianne ^a   Le, Elizabeth N ^a,b   Boin, Francesco ^a   Hummers, Laura K ^a   Wigley, Fredrick M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CENTROMERE ANTIBODY; DNA DIRECTED RNA POLYMERASE III; DNA TOPOISOMERASE; HLA DRB1 ANTIGEN;

AFRICAN AMERICAN; ARTICLE; CANCER MORTALITY; COLD EXPOSURE; COLD SENSITIVITY; DIFFUSE SCLERODERMA; DISEASE CLASSIFICATION; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FOLLOW UP; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; GENOTYPE; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HEART CATHETERIZATION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; MUSCLE DISEASE; OVERALL SURVIVAL; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RAYNAUD PHENOMENON; SCLERODERMA; SOCIAL STATUS; SOCIOECONOMICS; SURVIVAL RATE;

AFRICAN AMERICANS; FEMALE; HUMANS; LUNG; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; RISK ASSESSMENT; SCLERODERMA, DIFFUSE; SCLERODERMA, LOCALIZED; SCLERODERMA, SYSTEMIC; SOCIAL CLASS; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84880272365     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0b013e31829be125     Document Type: Article

References (43)

1. Alshekhlee A, Miles JD, Katirji B, Preston DC, Kaminski HJ. Incidence and mortality rates of myasthenia gravis and myasthenic crisis in US hospitals. Neurology. 2009;72:1548-1554.
2. Assassi S, Del JD, Sutter K, McNearney TA, Reveille JD, Karnavas A, Gourh P, Estrada YMR, Fischbach M, Arnett FC, Mayes MD. Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheum. 2009;61:1403-1411.
3. Beall AD, Nietert PJ, Taylor MH, Mitchell HC, Shaftman SR, Silver RM, Smith EA, Bolster MB. Ethnic disparities among patients with pulmonary hypertension associated with systemic sclerosis. J Rheumatol. 2007;34:1277-1282.
4. Berry CE, Wise RA. Interpretation of pulmonary function test: Issues and controversies. Clin Rev Allergy Immunol. 2009;37:173-180.
5. Burek CL, Rose NR, Guire KE, Hoffman WH. Thyroid autoantibodies in black and in white children and adolescents with type 1 diabetes mellitus and their first degree relatives. Autoimmunity. 1990;7:157-167.
6. Cox DR. Regression models and life tables. J R Stat Soc EB. 1972;34:187-220.
7. Dooley MA, Hogan S, Jennette C, Falk R. Cyclophosphamide therapy for lupus nephritis: Poor renal survival in black Americans. Glomerular Disease Collaborative Network. Kidney Int. 1997;51:1188-1195.
8. Fessel WJ. Systemic lupus erythematosus in the community. Incidence, prevalence, outcome, and first symptoms; the high prevalence in black women. Arch Intern Med. 1974;134:1027-1035.
9. Greidinger EL, Flaherty KT, White B, Rosen A, Wigley FM, Wise RA. African-American race and antibodies to topoisomerase I are associated with increased severity of scleroderma lung disease. Chest. 1998;114:801-807.
10. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159:179-187.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Statist Assn. 1958;53:457-481.
12. Knudson RJ, Kaltenborn WT, Knudson DE, Burrows B. The single-breath carbon monoxide diffusing capacity. Reference equations derived from a healthy nonsmoking population and effects of hematocrit. Am Rev Respir Dis. 1987;135:805-811.
13. Laing TJ, Gillespie BW, Toth MB, Mayes MD, Gallavan RH Jr, Burns CJ, Johanns JR, Cooper BC, Keroack BJ, Wasko MC, Lacey JV Jr, Schottenfeld D. Racial differences in scleroderma among women in Michigan. Arthritis Rheum. 1997;40:734-742.
14. LaPorte RE, Tajima N, Dorman JS, Cruickshanks KJ, Eberhardt MS, Rabin BS, Atchison RW, Wagener DK, Becker DJ, Orchard TJ, et al. Differences between blacks and whites in the epidemiology of insulin-dependent diabetes mellitus in Allegheny County, Pennsylvania. Am J Epidemiol. 1986;123:592-603.
15. Lee P, Langevitz P, Alderdice CA, Aubrey M, Baer PA, Baron M, Buskila D, Dutz JP, Khostanteen I, Piper S, et al. Mortality in systemic sclerosis (scleroderma). Q J Med. 1992;82:139-148.
16. Leinwand I, Duryee AW, Richter MN. Scleroderma; based on a study of over 150 cases. Ann Intern Med. 1954;41: 1003-1041.
17. Leroy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr, Rowell N, Wollheim F. Scleroderma (systemic sclerosis): Classification, subsets and pathogenesis. J Rheumatol. 1988;15: 202-205.
18. Leroy EC, Medsger TA Jr. Criteria for the classification of early systemic sclerosis. J Rheumatol. 2001;28:1573-1576.
19. Lim KN, Casanova RL, Boyer TD, Bruno CJ. Autoimmune hepatitis in African Americans: Presenting features and response to therapy. Am J Gastroenterol. 2001;96:3390-3394.
20. Lorenzi M, Cagliero E, Schmidt NJ. Racial differences in incidence of juvenile-onset type 1 diabetes: Epidemiologic studies in southern California. Diabetologia. 1985;28:734-738.
21. Manno RL, Wigley FM, Gelber AC, Hummers LK. Late-age onset systemic sclerosis. J Rheumatol. 2011;38:1317-1325.
22. Masi AT, D'Angelo WA. Epidemiology of fatal systemic sclerosis (diffuse scleroderma). A 15-year survey in Baltimore. Ann Intern Med. 1967;66:870-883.
23. Mayes MD, Lacey JV Jr, Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, Schottenfeld D. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum. 2003;48:2246-2255.
24. Medsger TA Jr, Masi AT. Epidemiology of systemic sclerosis (scleroderma). Ann Intern Med. 1971;74:714-721.
25. Medsger TA Jr, Masi AT, Rodnan GP, Benedek TG, Robinson H. Survival with systemic sclerosis (scleroderma). A life-table analysis of clinical and demographic factors in 309 patients. Ann Intern Med. 1971;75:369-376.
26. Medsger TA Jr, Silman AJ, Steen VD, Black CM, Akesson A, Bacon PA, Harris CA, Jablonska S, Jayson MI, Jimenez SA, Krieg T, Leroy EC, Maddison PJ, Russell ML, Schachter RK,Wollheim FA, Zacharaie H. A disease severity scale for systemic sclerosis: Development and testing. J Rheumatol. 1999;26:2159-2167.
27. Mikuls TR, Sayles H, Yu F, Levan T, Gould KA, Thiele GM, Conn DL, Jonas BL, Callahan LF, Smith E, Brasington R, Moreland LW, Reynolds RJ, Bridges SL Jr. Associations of cigarette smoking with rheumatoid arthritis in African Americans. Arthritis Rheum. 2010;62:3560-3568.
28. Nietert PJ, Silver RM. Patterns of hospital admissions and emergency room visits among patients with scleroderma in South Carolina, USA. J Rheumatol. 2003;30:1238-1243.
29. Nietert PJ, Silver RM, Mitchell HC, Shaftman SR, Tilley BC. Demographic and clinical factors associated with in-hospital death among patients with systemic sclerosis. J Rheumatol. 2005;32: 1888-1892.
30. Oh SJ, Morgan MB, Lu L, Hatanaka Y, Hemmi S, Young A, Claussen GC. Racial differences in myasthenia gravis in Alabama. Muscle Nerve. 2009;39:328-332.
31. Okayasu I, Hara Y, Nakamura K, Rose NR. Racial and age-related differences in incidence and severity of focal autoimmune thyroiditis. Am J Clin Pathol. 1994;101:698-702.
32. Osler W. The Principles and Practice of Medicine. 4th ed. New York: Appleton; 1901.
33. Peters MG, Di Bisceglie AM, Kowdley KV, Flye NL, Luketic VA, Munoz SJ, Garcia-Tsao G, Boyer TD, Lake JR, Bonacini M, Combes B. Differences between Caucasian, African American, and Hispanic patients with primary biliary cirrhosis in the United States. Hepatology. 2007;46:769-775.
34. Peto R, Peto J. Asymptotically efficient rank invariant procedures. J R Statist Soc EA. 1972;135:185-207.
35. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Arthritis Rheum. 1980;23:581-590.
36. Sharif R, Fritzler MJ, Mayes MD, Gonzalez EB, McNearney TA, Draeger H, Baron M, Furst DE, Khanna DK, del Junco DJ, Molitor JA, Schiopu E, Phillips K, Seibold JR, Silver RM, Simms RW, Perry M, Rojo C, Charles J, Zhou X, Agarwal SK, Reveille JD, Assassi S, Arnett FC. Anti-fibrillarin antibody in African American patients with systemic sclerosis: Immunogenetics, clinical features, and survival analysis. J Rheumatol. 2011;38:1622-1630.
37. Steen V, Domsic RT, Lucas M, Fertig N, Medsger TA. A clinical and serologic comparison of African-American and Caucasian patients with systemic sclerosis. Arthritis Rheum. 2012;64:2986-2994.
38. Steen VD, Costantino JP, Shapiro AP, Medsger TA Jr. Outcome of renal crisis in systemic sclerosis: Relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med. 1990;113: 352-357.
39. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000;133:600-603.
40. Traub YM, Shapiro AP, Rodnan GP, Medsger TA, McDonald RH Jr, Steen VD, Osial TA Jr, Tolchin SF. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine (Baltimore). 1983;62:335-352.
41. Tuffanelli DL, Winkelmann RK. Systemic scleroderma, a clinical study of 727 cases. Arch Dermatol. 1961;84:359-371.
42. Velayos EE, Masi AT, Stevens MB, Shulman LE. The "CREST" syndrome. Comparison with systemic sclerosis (scleroderma). Arch Intern Med. 1979;139:1240-1244.
43. Wagenknecht LE, Roseman JM, Alexander WJ. Epidemiology of IDDM in black and white children in Jefferson County, Alabama, 1979-1985. Diabetes. 1989;38:629-633.